贝伐珠单抗维持治疗小细胞肺癌1例并文献复习  

Anti-angiogenesis therapy with bevacizumab as maintenance treatment in a patient with small cell lung cancer: A case report and literature review

作　　者：薛鹏 周磊[2] 李林潞 徐芃芃 王宁军[2] 王芳[2] 朱世杰[2] Xue Peng;Zhou Lei;Li Linlu;Xu Pengpeng;Wang Ningjun;Wang Fang;Zhu Shijie(Beijing University of Chinese Medicine,Beijing 100029,China;Department of Oncology,Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China)

机构地区：[1]北京中医药大学,北京100029 [2]中国中医科学院望京医院肿瘤科,北京100102

出　　处：《现代肿瘤医学》2019年第3期411-415,共5页Journal of Modern Oncology

摘　　要：目的:探讨贝伐珠单抗维持治疗小细胞肺癌对无进展生存时间及总生存时间的影响。方法:本文报道1例广泛期小细胞肺癌贝伐珠单抗联合化疗5个周期后继续贝伐珠单抗维持治疗8个周期病例,并对相关文献进行复习。结果:患者无进展生存时间为10个月。结论:贝伐珠单抗维持治疗广泛期小细胞肺癌可以延长无进展生存期,延长生存期。Objective:To investigate the effect of bevacizumab on the progression-free survival and overall survival of patients with extensive stage small cell lung cancer.Methods:We reported a case with 5 cycles of chemotherapy combined bevacizumab and 8 cycles of bevacizumab maintained therapy,and review the relevant literature.Results:The patient achieved 10 months progression-free survival.Conclusion:Bevacizumab for the treatment of extensive small cell lung cancer can prolong progression-free survival and prolong survival.

关 键 词：广泛期小细胞肺癌 贝伐珠单抗 生存期 

分 类 号：R734.2[医药卫生—肿瘤]